Herpes simplex virus (HSV-1)

news

Gene editing for HSV-1 shows significant reduction of viral load

15 May 2024 | By Drug Target Review

The experimental therapy eliminated 90 percent of HSV-1 after facial infection and 97 percent of HSV-1 after genital infection.

news

Developing an effective vaccine for herpes simplex virus

13 February 2024 | By Drug Target Review

Researchers have identified key differences between HSV-1 and HSV-2 and have developed monoclonal antibodies that could treat neonatal infections.

article

Developing modern vaccines against an underrecognised foe

5 April 2022 | By Dr Sandeep Basnet (Moderna Therapeutics)

Messenger RNA (mRNA) may be the ‘skeleton key’ that unlocks the door to fight latent viral infections that have plagued researchers for generations. Dr Sandeep Basnet, Director, Clinical Development at Moderna Therapeutics explores modern vaccine development and why mRNA is taking centre stage.

news

Scientists identify protein that prevents HSV-1 brain damage

20 October 2021 | By Anna Begley (Drug Target Review)

Mammalian target of rapamycin complex 2 (mTORC2) was found to prevent brain damage in mice infected with herpes simplex virus 1 (HSV-1).

news

Scientists complete genomic study of herpes simplex virus

28 April 2020 | By Victoria Rees (Drug Target Review)

Researchers have unravelled the viral transcriptome and translatome of the herpes simplex virus (HSV-1) to aid disease research and immunotherapy.